---
title: "Merck & Co., Inc. (MRK.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MRK.US.md"
symbol: "MRK.US"
name: "Merck & Co., Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T19:41:04.108Z"
locales:
  - [en](https://longbridge.com/en/quote/MRK.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MRK.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MRK.US.md)
---

# Merck & Co., Inc. (MRK.US)

## Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.merck.com](https://www.merck.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 37 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.89% |  |
| Net Profit YoY | -48.75% |  |
| P/B Ratio | 6.06 |  |
| Dividend Ratio | 2.95% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 278003436152.40 |  |
| Revenue | 65768000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 18.97% | A |
| Profit Margin | 13.59% | B |
| Gross Margin | 76.21% | A |
| Revenue YoY | 2.89% | C |
| Net Profit YoY | -48.75% | D |
| Total Assets YoY | 11.78% | B |
| Net Assets YoY | -5.10% | D |
| Cash Flow Margin | 200.22% | B |
| OCF YoY | 2.89% | C |
| Turnover | 0.54 | C |
| Gearing Ratio | 64.31% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Merck & Co., Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.89%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.75%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.06",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.95%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "278003436152.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "65768000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "18.97%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "13.59%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "76.21%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.89%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-48.75%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "11.78%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.10%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "200.22%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "2.89%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "64.31%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 31.11 | 47/190 | 15.86 | 13.14 | 11.87 |
| PB | 6.06 | 158/190 | 5.47 | 4.55 | 4.20 |
| PS (TTM) | 4.23 | 92/190 | 4.38 | 3.59 | 3.20 |
| Dividend Yield | 2.95% | 13/190 | 3.93% | 3.49% | 2.89% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **29**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 15 | 52% |
| Overweight | 4 | 14% |
| Hold | 10 | 34% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 114.45 |
| Highest Target | 150.00 |
| Lowest Target | 100.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MRK.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MRK.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MRK.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MRK.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**